Although immunotherapy has shown promising results in the treatment of certain breast cancer subtypes, such as triple negative breast cancer, its efficacy in hormone receptor-positive subtypes, such as hormone receptor+/HER2−, remains limited. The gene discussed is NR4A1; the disease is breast carcinoma.